
The full results of a study involving the newest cholesterol fighting drug, Vytorin, surfaced on the Internet Sunday to appalled audiences because the drug failed to improve heart disease and limit complete plaque buildup in the arteries.
Millions of Americans began to consume the drug when it hit pharmacies in 2004, racking in $5 billion in sales despite limited proof of benefit.
The results show the drug had "no result-zilch. In no sub-group, in no segment, was there any added benefit," for reducing plaque, said Dr. John Kastelein, the Dutch scientist who led the study.
Even though Vytorin works as intended to reduce three key factors of heart disease by combining Zocor with Schering-Plough Corp.'s Zetia, which went on sale in 2002 and attacks cholesterol in a different way, it took drugmakers nearly two years after the study's completion to release accurate results.
Doctors urge those with clogged arteries and risk for heart disease to go back to older treatments for high cholesterol, such as diet, exercise, and drugs proven to reduce risk.
Related Articles:

Babies born prematurely have a risk of mortality after infancy and a recent study shows that these preemies may have a decreased reproductive rate or a chance of delivering prematurely.





